Christopher H. Schott advises clients in the pharmaceutical, healthcare, and life science industries in connection with drug price reporting and commercial contracting. His practice focuses on assisting pharmaceutical manufacturers with drug price reporting and other regulatory and compliance obligations under the Medicaid, Medicare, and Public Health Service (340B) programs. Chris also supports clients with regard to corporate and commercial contracting matters related to the healthcare sector. In addition, he advises pharmaceutical manufacturers with regard to industry-specific price reporting aspects of their periodic reporting obligations under the U.S. federal securities laws.
Chris has also advised clients in the life science and other industries in connection with corporate and securities law matters, with a focus on corporate governance, compliance with the U.S. federal securities laws, private and public offerings, and mergers and acquisitions.
Prior to joining Hogan Lovells, Chris was an associate at a leading national law firm, where he represented Wall Street financial institutions and investment banks. Chris was employed in the telecommunication and information technology sectors before attending law school.
In law school, Chris was a George Washington Scholar and a member of The George Washington International Law Review. He is a recipient of the law school’s Richard L. Teberg Award for Excellence in securities law.